Recently, a biomarker risk score that included high-sensitivity troponin T, NT-proBNP, high-sensitivity C-reactive protein and left ventricular hypertrophy on electrocardiogram was shown to stratify HF risk in patients with dysglycemia (diabetes and pre-diabetes) and inform the allocation of HF prevention therapies in these patients [13]. Here, NPPB is linked to diabetes mellitus.